Syros Pharmaceuticals Inc. (NASDAQ:SYRS)’s traded shares stood at 1.28 million during the latest session, with the company’s beta value hitting 1.58. At the last check today, the stock’s price was $1.84, to imply an increase of 17.20% or $0.27 in intraday trading. The SYRS share’s 52-week high remains $8.17, putting it -344.02% down since that peak but still an impressive 22.28% since price per share fell to its 52-week low of $1.43. The company has a valuation of $49.18M, with an average of 0.18 million shares in intraday trading volume over the past 10 days and average of 253.51K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Syros Pharmaceuticals Inc. (SYRS), translating to a mean rating of 1.00. Of 7 analyst(s) looking at the stock, 0 analyst(s) give SYRS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.72.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Syros Pharmaceuticals Inc. (NASDAQ:SYRS) trade information
After registering a 17.20% upside in the latest session, Syros Pharmaceuticals Inc. (SYRS) has traded red over the past five days. The 5-day price performance for the stock is 21.45%, and 13.93% over 30 days. With these gigs, the year-to-date price performance is -76.38%. Short interest in Syros Pharmaceuticals Inc. (NASDAQ:SYRS) saw shorts transact 0.96 million shares and set a 1.96 days time to cover.
The extremes give us $13 and $30 for target low and target high price respectively. As such, SYRS has been trading -1530.43% off suggested target high and -606.52% from its likely low.
Syros Pharmaceuticals Inc. (SYRS) estimates and forecasts
Looking at statistics comparing Syros Pharmaceuticals Inc. share performance against respective industry, we note that the company has outperformed competitors. Syros Pharmaceuticals Inc. (SYRS) shares are -69.49% down over the last 6 months, with its year-to-date growth rate higher than industry average at 55.74% against 17.20%. Revenue is forecast to grow 49.70% this quarter before jumping 66.10% for the next one. The rating firms project that company’s revenue will shrink -91.20% compared to the previous financial year.
Revenue forecast for the current quarter as set by 4 analysts is 450k. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 450k.Earnings reports from the last fiscal year show that sales brought in 3.76M and 387k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -88.00% before jumping 16.30% in the following quarter.
SYRS Dividends
Syros Pharmaceuticals Inc. has its next earnings report out on 2024-Nov-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Syros Pharmaceuticals Inc. (NASDAQ:SYRS)’s Major holders
Syros Pharmaceuticals Inc. insiders hold 1.32% of total outstanding shares, with institutional holders owning 81.10% of the shares at 82.19% float percentage. In total, 81.10% institutions holds shares in the company.
